Drugs / S. boulardii
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05261152 | Nov 2017 → Dec 2018 | diarrheal disease, respiratory tract infectious disorder | Clinical Centre of Serbia | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07168304 | Feb → Jul 2025 | acute diarrhea | Muhammad Aamir Latif | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02310425 Comparator | Mar → Jul 2013 | — | Lingfen Xu, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S. boulardii | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02310425 ↗ |
| Modality | Other / unclassified | “S. boulardii is a non-pathogenic probiotic yeast.” NCT02310425 ↗ |